DDInter38 DDInter1055
Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This recombinant form differs from native interleukin-2 in the following ways: a) Aldesleukin is not glycosylated because it is derived from E. coli; b) the molecule has no N-terminal alanine; the codon for this amino acid was deleted during the genetic engineering procedure; c) the molecule has serine substituted for cysteine at amino acid position 125.
Levofloxacin is a fluoroquinolone antibiotic and the optical S-(-) isomer of racemic [ofloxacin]. It reportedly carries 8 to 128-fold more activity against both gram-negative and gram-positive bacteria compared to R-(+)-ofloxacin and remains stereochemically stable following administration (i.e. it does not invert to the inactive isomer). Levofloxacin, along with other quinolones such as [gatifloxacin] and [moxifloxacin], is a member of the third generation of fluoroquinolones, colloquially referred to as the "respiratory quinolones" due to improved activity against gram-positive bacteria commonly implicated in respiratory infections.[A31453,A190756] Levofloxacin was first approved by the FDA in 1996, and was approved in Canada and several South American countries soon after.
Aldesleukin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Enoxacin
Enoxacin {u} (Compound) resembles {v} (Compound) Levofloxacin
Aldesleukin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sparfloxacin
Sparfloxacin {u} (Compound) resembles {v} (Compound) Levofloxacin
Aldesleukin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Enoxacin
Enoxacin {u} (Compound) resembles {v} (Compound) Ciprofloxacin
Ciprofloxacin {u} (Compound) resembles {v} (Compound) Levofloxacin
Aldesleukin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Moxifloxacin
Moxifloxacin {u} (Compound) resembles {v} (Compound) Enoxacin
Enoxacin {u} (Compound) resembles {v} (Compound) Levofloxacin
Aldesleukin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cinoxacin
Cinoxacin {u} (Compound) binds {v} (Gene) SLC22A6
SLC22A6 {u} (Gene) is bound by {v} (Compound) Levofloxacin
Aldesleukin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cinoxacin
Cinoxacin {u} (Compound) causes {v} (Side Effect) Headache
Headache {u} (Side Effect) is caused by {v} (Compound) Levofloxacin
Aldesleukin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Gemifloxacin
Gemifloxacin {u} (Compound) resembles {v} (Compound) Sparfloxacin
Sparfloxacin {u} (Compound) resembles {v} (Compound) Levofloxacin
Aldesleukin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Epirubicin
Epirubicin {u} (Compound) upregulates {v} (Gene) DNMT3A
DNMT3A {u} (Gene) is downregulated by {v} (Compound) Levofloxacin
Aldesleukin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Methyldopa
Methyldopa {u} (Compound) upregulates {v} (Gene) ERAP2
ERAP2 {u} (Gene) is upregulated by {v} (Compound) Levofloxacin
Aldesleukin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Epirubicin
Epirubicin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Enoxacin
Enoxacin {u} (Compound) resembles {v} (Compound) Levofloxacin
Aldesleukin may cause a minor interaction that can limit clinical effects when taken with Enoxacin and Enoxacin (Compound) resembles Levofloxacin (Compound)
Aldesleukin may cause a minor interaction that can limit clinical effects when taken with Sparfloxacin and Sparfloxacin (Compound) resembles Levofloxacin (Compound)
Aldesleukin may cause a minor interaction that can limit clinical effects when taken with Enoxacin and Enoxacin (Compound) resembles Ciprofloxacin (Compound) and Ciprofloxacin (Compound) resembles Levofloxacin (Compound)
Aldesleukin may cause a minor interaction that can limit clinical effects when taken with Moxifloxacin and Moxifloxacin (Compound) resembles Enoxacin (Compound) and Enoxacin (Compound) resembles Levofloxacin (Compound)
Aldesleukin may cause a minor interaction that can limit clinical effects when taken with Cinoxacin and Cinoxacin (Compound) binds SLC22A6 (Gene) and SLC22A6 (Gene) is bound by Levofloxacin (Compound)
Aldesleukin may cause a minor interaction that can limit clinical effects when taken with Cinoxacin and Cinoxacin (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Levofloxacin (Compound)
Aldesleukin may cause a minor interaction that can limit clinical effects when taken with Gemifloxacin and Gemifloxacin (Compound) resembles Sparfloxacin (Compound) and Sparfloxacin (Compound) resembles Levofloxacin (Compound)
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin (Compound) upregulates DNMT3A (Gene) and DNMT3A (Gene) is downregulated by Levofloxacin (Compound)
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Methyldopa and Methyldopa (Compound) upregulates ERAP2 (Gene) and ERAP2 (Gene) is upregulated by Levofloxacin (Compound)
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin may cause a minor interaction that can limit clinical effects when taken with Enoxacin and Enoxacin (Compound) resembles Levofloxacin (Compound)